Hallandale Pharmacy

• Pharmacy Profile Name: Hallandale Pharmacy
• Website: hallandalerx.com
• Address: 2666 SW 36th St, Fort Lauderdale, FL 33312
• Owner/President: David G. Rabbani
• Pharmacy Type: 503A state-licensed compounding pharmacy
• Accreditations: PCAB accredited
• GLP-1 Compounding: Semaglutide, Tirzepatide, Liraglutide
• Licensing: Multi-state (specific count not publicly confirmed)

About the Pharmacy

Hallandale Pharmacy describes itself as a 503A designated pharmacy held to USP standards, committed to exceeding those standards for its trusted practitioners and their patients, delivering tailored prescriptions in the shortest amount of time. The pharmacy operates under the legal entity Pharmcore Inc., with David G. Rabbani as owner and president, and is headquartered in Fort Lauderdale, Florida.

Hallandale became one of the most widely recognized pharmacy names in the consumer-facing compounded GLP-1 space, primarily through its partnerships with high-profile telehealth platforms during the shortage era. Its name became familiar to a large number of GLP-1 patients who received vials branded or disclosed as coming from Hallandale through their telehealth providers.

GLP-1 Compounding

Hallandale offers injectable GLP-1 options, including Semaglutide, Tirzepatide, and Liraglutide, positioning itself as a provider of personalized GLP-1 therapy for conditions including diabetes and obesity.

As a 503A designated pharmacy, adhering to USP <797> standards is fundamental to Hallandale’s operations, and the pharmacy states it goes beyond compliance through ongoing product testing, scientific research, validated processes, regular facility maintenance, and comprehensive personnel training. It holds PCAB accreditation, demonstrating commitment to industry compounding standards.

Despite these stated commitments, efficacy complaints from patients have been a consistent pattern across multiple platforms.

Type of Pharmacy

Hallandale Pharmacy operates as a 503A facility, which means it compounds medications on a prescription-by-prescription basis. Unlike 503B outsourcing facilities, 503A pharmacies aren’t required to follow the same strict FDA manufacturing standards or submit to regular FDA inspections.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

Regulatory History:

A March 11, 2020, FDA Warning Letter was issued following a July 2018 inspection at Hallandale’s prior facility at 1109 East Hallandale Beach Boulevard. The FDA found that the pharmacy did not receive valid prescriptions for individually-identified patients for a portion of drug products produced, and that sterile drug products were prepared, packed, or held under insanitary conditions whereby they may have become contaminated — putting patients at risk.

In May 2022, the FDA issued a Warning Letter Closeout, confirming that it had completed an evaluation of Hallandale’s corrective actions and that the pharmacy appeared to have adequately addressed the violations from the 2020 Warning Letter.

Following the closeout, the FDA inspected the pharmacy again from September 13 to September 24, 2021, this time at the Fort Lauderdale location, and issued a Form FDA 483 citing poor sterile practices, referring the matter to the Florida State Board of Pharmacy for follow-up. The outcome of that referral is not publicly documented.

States Licensed In

Hallandale ships nationally through its telehealth platform partners. Its specific multi-state licensing footprint is not comprehensively published on its website. Based on its widespread telehealth partnerships and national patient base, it is licensed in multiple states, though the exact count is not publicly confirmed.

Telehealth Providers They Work With

Hallandale has been publicly named or confirmed as a pharmacy partner by several notable telehealth platforms:

• Zappy Health — multiple BBB complaints from Zappy Health patients confirm Hallandale as the compounding pharmacy fulfilling their tirzepatide and semaglutide orders
• Lavender Sky Health — named in patient social media discussions as a Hallandale pharmacy partner
• Amble Health — referenced in social media as an Amble Health pharmacy partner; patients shared Hallandale unboxing content for Amble-prescribed GLP-1s
• Mochi Health — referenced in patient forums as a prior Hallandale partner, with indications of a transition away from Hallandale
• IVIM Health — referenced in social media alongside Hallandale as a telehealth platform using Hallandale for GLP-1 fulfillment

Pricing from Reviews

Hallandale’s pricing varies depending on which telehealth provider or clinic partners with them. Based on customer reports, monthly costs typically range from $230 to $390 per vial. Patients purchase through third-party telehealth providers that mark up the price from Hallandale’s wholesale cost.

Overall Reviews

Patient reviews of Hallandale are sharply polarized, with a significant volume of efficacy complaints that distinguishes it from most pharmacies in this series.

Positive experiences exist; BBB records include patients who report meaningful weight loss and good service interactions. However, a recurring and consistent pattern of complaints across BBB, Reddit, and patient forums raises meaningful quality questions:

Multiple BBB complaints describe medication that appeared visibly thinner than expected, in one case described as almost indistinguishable from saline, with zero weight loss results despite proper dosing and dosage increases. Patients who had previously used GLP-1 medications from other pharmacies reported dramatically different results when switching to the Hallandale-sourced product.

Serious efficacy complaints note that multiple customers report receiving medication that appeared diluted or watery, with zero weight loss results despite proper dosing

Hallandale’s standard response to potency complaints references independent Certificate of Analysis results from lot testing and states that batch testing showed no irregularities — but the frequency of similar complaints across unrelated patients and platforms is notable.